Neprinol

Fibrocystic breast disease and fibrocystic breast condition are one and the same thing. In fact, there is now a trend to use the term "condition" rather more because of the obvious connotations associated with the word "disease". It is a condition that is characterized by lumpiness in either one, or both breasts, (usually both breasts are affected) often causing discomfort, the levels of which can vary from woman to woman.

The condition affects up to 60% of all women and is most prevalent between the ages of 30 to 50 years of age. The incidence of the condition drops dramatically once the menopause has set in.

The severity of FBC varies from person to person. In some women the condition occurs only prior to her menstruation cycle, may often be painless, and the lumps, which form during this period, will disappear again and are therefore undetectable once the menstruation cycle is over. In other women, the condition can be more chronic, the lumps being detectable at all times, and causing severe discomfort.

Fibrocystic breast condition (FBC), is totally benign, meaning that it is not a malignant cancer, although understandably many women fear the worst when they first become aware of the lumps. However, a quick visit to the doctor will establish a diagnosis and can alleviate any fears on this score.

The concern for both women and their doctors is that FBC can also make any underlying breast cancer difficult to diagnose, and therefore great care needs to be taken when the examination is made.

But once FBC has been diagnosed, the next thing you will want to know is: Are there any effective treatments available today on the market? - The answer is yes, there are.

There is one product in particular that has been the subject of intense excitement and debate, and that is Neprinol.

Neprinol is seen by some as being a cure-all treatment for many ailments and the reason for this is the way that it is formulated, and what it has been designed to do. Neprinol has been classed as an enzyme therapy. Its unique selling point is the use of the enzymes Serrapeptase and Nattokinase, which whilst recognizable as digestive aids, are more pointedly relevant as body system anti-inflammatory aids. It is Neprinol's characteristic of fibrin modulation that explains its wide prescriptive recommendation. The simple fact of the matter is that Neprinol effectively combats any condition resulting from an excess of fibrin, just like in the case of FBC.
Syntol
The exciting thing about Neprinol is that it is clinically proven, and is safe to use. The only minor side effects that have been reported by a minority of users new to the product are transitory and disappear within 7 to 14 days, never to reappear again. These side effects can include headache, slight nausea, and in some cases diarrhea, and all are related to the body's "detox" reaction as excess fibrin is broken down and leached out through the lymphatic system.

Neprinol can bring permanent, fast acting, safe relief to the symptoms of FBC and is available to purchase online.

An imbalance in natural hormone levels, as well as exposure to hormone-like substances (xenosteroids) from pharmaceutical drugs and environmental factors, can evoke many disturbances in the female reproductive tissues. Such imbalances may trigger abnormal tissue growth within the breast and other female reproductive areas. This activity within the uterus can lead to the development of fibrin nests and eventually the growth of fibroids.

This is why Fibroid growth is thought by experts to be closely related with estrogen dominance and is said to be a prime contributor to the deregulation of normal function experienced by not only women approaching, transitioning, and resolving the challenge of menopause, but also young women experiencing difficulty when fertility begins also referred to as menarche.

The imbalance is initially characterized by a number of factors:

-A sudden decrease in DHEA due to stress, aging, poor diet, side effects of prescription drugs etc.

-Decrease in progesterone effect due to absolute decrease in synthesis secondary to inadequate cholesterol down-conversion and increasing insensitivity of progesterone receptors.

-The activation of a cross-conversion pathway which then forces progesterone to act as a source for the synthesis of estrogens thereby decreasing both its bioavailability as a hormone, and as a substrate for the formation of adrenal cortical hormones.

Like most endocrinology this concept is difficult for the average person as well as many physicians to fully comprehend.This concept is important because, it demonstrates that the best way to address conditions such as abnormal tissue growth and inflammation, is by providing the body with natural compounds that it can use to enhance processes that it already has in place to decrease symptoms and potentially undo tissue changes.

The inclusion of a DHEA supplement may indirectly increase progesterone synthesis and act to alleviate the need for available progesterone scavenged to promote a significant source for the synthesis of estrogen; relying less on progesterone as source for estrogen conversion allowing progesterone to act freely opposing estrogen.

FibroVera is a proprietary blend of microbial and botanical components selected to address these hormonal imbalances. As mentioned earlier these imbalances such as estrogen dominance activate the secretion of excess fibrin which may lead to abnormal cell formation in the breast and uterine tissue while increasing symptoms of PMS.

FibroVera also provides fibrinolytic enzymes a fibrin eating enzymes and cofactors that are specifically selected to address excess fibrin buildup; the primary components of endometriosis or fibroids. A mildly tipping of hormonal equilibration in favor of balance can significantly reduce the speed and intensity at which fibroids can grow. This allows the fibrinolytic enzymes in FibroVera to soften, breakup and eventually dissolve abnormal tissue development without significant opposition.

FibroVera is intended to modulate hormonal response, restoring inherent processes in a woman

Syntol

Partager cet article